Oncology · Familial Adenomatous PolyposisTrial Updateclinicalmid-term

Phase II Trial of TPST-1495 in Familial Adenomatous Polyposis Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:35:03 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase II trial of TPST-1495 represents a significant opportunity to address unmet medical needs in the treatment of Familial Adenomatous Polyposis (FAP). If successful, it could redefine treatment protocols and create competitive advantages in the oncology space. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 26 ranked evidence items (9 high-relevance).

Strategic Assessment

The strongest clinical anchor is An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (ClinicalTrials.gov), entity match (tpst-1495). In Oncology · Familial Adenomatous Polyposis, 6 regulatory and 4 competitive items passed relevance filtering for TPST-1495. Success in this trial could lead to a new treatment option, potentially capturing market share from existing therapies and enhancing revenue streams in the oncology sector.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. If successful, TPST-1495 could position itself as a novel treatment option for FAP, impacting current management strategies.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The trial's outcomes will be critical for future regulatory submissions, influencing approval timelines and labeling for TPST-1495 as a treatment for FAP.

Key Risks

Elevated medium regulatory exposure for TPST-1495 could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis) could weigh on TPST-1495 through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Success in this trial could lead to a new treatment option, potentially capturing market share from existing therapies and enhancing revenue streams in the oncology sector.
Upside for TPST-1495 may improve if An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
How we engage and involve patients and the public in our regulatory decision-making.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
ClinicalTrials.govhigh relevance
Entity match (tpst-1495)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Diabetes Care for Breast Cancer Patients
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

TPST-1495
National Cancer Institute

Commercial impact

medium

Success in this trial could lead to a new treatment option, potentially capturing market share from existing therapies and enhancing revenue streams in the oncology sector.

Regulatory impact

medium

The trial's outcomes will be critical for future regulatory submissions, influencing approval timelines and labeling for TPST-1495 as a treatment for FAP.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.